Modalis Therapeutics is a Japanese bio-venture that develops a unique genome editing technology "CRISPR-GNDM" that does not cut genes, which is more efficient and safer than conventional gene editing technology. By using "CRISPR-GNDM", Modalis Therapeutics develops therapeutic agents for gene-derived intractable diseases for which there is no therapeutic agent yet.